Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, open-label study of orally administered PAX-1 in combination with standard of care treatment in patients with newly diagnosed or recurrent glioblastoma
Novotech (Australia) Pty Limited
This is a non-randomised trial with two experimental arms. Arm 1 will consistent of people with newly diagnosed glioblastoma, and Arm 2 will consist of people with recurrent glioblastoma. Participants will receive a daily 15mg oral dose of PAX-1 (Sodium meta-arsenite) in combination with investigator choice standard of care until disease progression, patients withdraw due to tolerability, or patients withdraw consent.